In Vitro Investigation, Pharmacokinetics, and Disposition of Imeglimin, a Novel Oral Antidiabetic Drug, in Preclinical Species and Humans von Clémence, Chevalier, Fouqueray, Pascale, Sébastien, Bolze

Volltext

Imeglimin amplifies glucose-stimulated insulin release from diabetic islets via a distinct mechanism of action von Hallakou-Bozec, Sophie, Kergoat, Micheline, Fouqueray, Pascale, Bolze, Sébastien, Moller, David E

Volltext

Mechanism of action of Imeglimin: A novel therapeutic agent for type 2 diabetes von Hallakou‐Bozec, Sophie, Vial, Guillaume, Kergoat, Micheline, Fouqueray, Pascale, Bolze, Sébastien, Borel, Anne‐Laure, Fontaine, Eric, Moller, David E.

Volltext

Absence of QTc prolongation in a thorough QT study with imeglimin, a first in class oral agent for type 2 diabetes mellitus von Dubourg, Julie, Perrimond-Dauchy, Sandrine, Felices, Mathieu, Bolze, Sébastien, Voiriot, Pascal, Fouqueray, Pascale

Volltext

Imeglimin lowers glucose primarily by amplifying glucose-stimulated insulin secretion in high-fat-fed rodents von Perry, Rachel J, Cardone, Rebecca L, Petersen, Max C, Zhang, Dongyan, Fouqueray, Pascale, Hallakou-Bozec, Sophie, Bolze, Sébastien, Shulman, Gerald I, Petersen, Kitt Falk, Kibbey, Richard G

Volltext

Lack of Drug–Drug Interaction Between Cimetidine, a Renal Transporter Inhibitor, and Imeglimin, a Novel Oral Antidiabetic Drug, in Healthy Volunteers von Chevalier, Clémence, Perrimond-Dauchy, Sandrine, Dubourg, Julie, Fouqueray, Pascale, Bolze, Sébastien

Volltext

Phase 2 trial with imeglimin in patients with Type 2 diabetes indicates effects on insulin secretion and sensitivity von Theurey, Pierre, Thang, Carole, Pirags, Valdis, Mari, Andrea, Pacini, Giovanni, Bolze, Sébastien, Hallakou‐Bozec, Sophie, Fouqueray, Pascale

Volltext

Reduced lactic acidosis risk with Imeglimin: Comparison with Metformin von Theurey, Pierre, Vial, Guillaume, Fontaine, Eric, Monternier, Pierre‐Axel, Fouqueray, Pascale, Bolze, Sébastien, Moller, David E., Hallakou‐Bozec, Sophie

Volltext

Deuterium‐Stabilized (R)‐Pioglitazone (PXL065) Is Responsible for Pioglitazone Efficacy in NASH yet Exhibits Little to No PPARγ Activity von Jacques, Vincent, Bolze, Sébastien, Hallakou‐Bozec, Sophie, Czarnik, Anthony W., Divakaruni, Ajit S., Fouqueray, Pascale, Murphy, Anne N., Van der Ploeg, Lex H.T., DeWitt, Sheila

Volltext

Efficacy and Safety of Imeglimin Monotherapy Versus Placebo in Japanese Patients With Type 2 Diabetes (TIMES 1): A Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Mul... von Dubourg, Julie, Fouqueray, Pascale, Thang, Carole, Grouin, Jean-Marie, Ueki, Kohjiro

Volltext

Imeglimin: A Clinical Pharmacology Review von Chevalier, Clémence, Fouqueray, Pascale, Bolze, Sébastien

Volltext

Imeglimin Does Not Induce Clinically Relevant Pharmacokinetic Interactions When Combined with Either Metformin or Sitagliptin in Healthy Subjects von Fouqueray, Pascale, Perrimond-Dauchy, Sandrine, Bolze, Sébastien

Volltext

Long‐term safety and efficacy of imeglimin as monotherapy or in combination with existing antidiabetic agents in Japanese patients with type 2 diabetes (TIMES 2): A 52‐week, open‐l... von Dubourg, Julie, Fouqueray, Pascale, Quinslot, Damien, Grouin, Jean‐Marie, Kaku, Kohei

Volltext

Pharmacokinetics of Imeglimin in Caucasian and Japanese Healthy Subjects von Fouqueray, Pascale, Chevalier, Clémence, Bolze, Sébastien

Volltext

Efficacy and safety of imeglimin in Japanese patients with type 2 diabetes: A 24‐week, randomized, double‐blind, placebo‐controlled, dose‐ranging phase 2b trial von Dubourg, Julie, Ueki, Kohjiro, Grouin, Jean‐Marie, Fouqueray, Pascale

Volltext

Efficacy and safety of imeglimin add‐on to insulin monotherapy in Japanese patients with type 2 diabetes (TIMES 3): A randomized, double‐blind, placebo‐controlled phase 3 trial wit... von Reilhac, Caroline, Dubourg, Julie, Thang, Carole, Grouin, Jean‐Marie, Fouqueray, Pascale, Watada, Hirotaka

Volltext

Evaluation of PXL065 – deuterium-stabilized (R)-pioglitazone in patients with NASH: A phase II randomized placebo-controlled trial (DESTINY-1) von Harrison, Stephen A., Thang, Carole, Bolze, Sébastien, Dewitt, Sheila, Hallakou-Bozec, Sophie, Dubourg, Julie, Bedossa, Pierre, Cusi, Kenneth, Ratziu, Vlad, Grouin, Jean-Marie, Moller, David E., Fouqueray, Pascale

Volltext

Pharmacokinetics of Imeglimin in Subjects with Moderate Hepatic Impairment von Chevalier, Clémence, Dubourg, Julie, Bolze, Sébastien, Fouqueray, Pascale

Volltext

Beneficial Effects of the Direct AMP-Kinase Activator PXL770 in In Vitro and In Vivo Models of X-Linked Adrenoleukodystrophy von Monternier, Pierre-Axel, Parasar, Parveen, Theurey, Pierre, Gluais Dagorn, Pascale, Kaur, Navtej, Nagaraja, Tavarekere N, Fouqueray, Pascale, Bolze, Sébastien, Moller, David E., Singh, Jaspreet, Hallakou-Bozec, Sophie

Volltext

The Efficacy and Safety of Imeglimin as Add-on Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Sitagliptin Monotherapy von FOUQUERAY, Pascale, PIRAGS, Valdis, DIAMANT, Michaela, SCHERNTHANER, Guntram, LEBOVITZ, Harold E, INZUCCHI, Silvio E, BAILEY, Clifford J

Volltext